Alyssum Therapeutics
Alyssum Therapeutics is pioneering B cell immunotherapy with a mission to transform patient lives by regulating the B cell immune response to treat complex diseases. Their lead candidate, AT1965, is in Phase 1 clinical trials for advanced solid malignancies, aiming to harness B cells' full immune response to improve cancer treatment outcomes.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Clinical-stage small-molecule inhibitor of an RNA cap methyltransferase (CMTR2)
A clinical-stage small-molecule therapeutic designed to inhibit a tumor-expressed RNA cap methyltransferase to generate immunogenic RNA signatures, recruit B cell responses and produce antitumor activity; progressed to first-in-human studies and evaluated in preclinical tumor models with reported combination activity with immune checkpoint inhibitors.
Clinical-stage small-molecule inhibitor of an RNA cap methyltransferase (CMTR2)
A clinical-stage small-molecule therapeutic designed to inhibit a tumor-expressed RNA cap methyltransferase to generate immunogenic RNA signatures, recruit B cell responses and produce antitumor activity; progressed to first-in-human studies and evaluated in preclinical tumor models with reported combination activity with immune checkpoint inhibitors.
Services
Enrollment of eligible patients into early-phase oncology clinical trials evaluating safety, tolerability, PK/PD and preliminary efficacy of investigational small molecules.
Enrollment of eligible patients into early-phase oncology clinical trials evaluating safety, tolerability, PK/PD and preliminary efficacy of investigational small molecules.
Expertise Areas
- B cell immunotherapy
- Small-molecule oncology therapeutics
- Preclinical tumor models and in vivo efficacy
- Translational research and biomarker-driven development
Key Technologies
- Small-molecule inhibitors
- Targeting of RNA cap methyltransferase (CMTR2)
- In vivo murine tumor models (e.g., 4T1)
- PK/PD analysis